Compare PASW & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASW | QNCX |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 19.9M |
| IPO Year | N/A | 2019 |
| Metric | PASW | QNCX |
|---|---|---|
| Price | $0.15 | $1.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 140.8K | ★ 1.5M |
| Earning Date | 05-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.08 |
| 52 Week High | $1.08 | $4.55 |
| Indicator | PASW | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 49.53 |
| Support Level | $0.13 | $0.10 |
| Resistance Level | $0.17 | $1.50 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 35.60 | 50.89 |
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.